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Abstract
Background: Transgenic RNAi holds promise as a simple, low-cost, and fast method for reverse
genetics in mammals. It may be particularly useful for producing animal models for hypomorphic
gene function. Inducible RNAi that permits spatially and temporally controllable gene silencing in
vivo will enhance the power of transgenic RNAi approach. Furthermore, because microRNA
(miRNA) targeting specific genes can be expressed simultaneously with protein coding genes,
incorporation of fluorescent marker proteins can simplify the screening and analysis of transgenic
RNAi animals.
Results: We sought to optimally express a miRNA simultaneously with a fluorescent marker. We
compared two construct designs. One expressed a red fluorescent protein (RFP) and a miRNA
placed in its 3' untranslated region (UTR). The other expressed the same RFP and miRNA, but the
precursor miRNA (pre-miRNA) coding sequence was placed in an intron that was inserted into the
3'-UTR. We found that the two constructs expressed comparable levels of miRNA. However, the
intron-containing construct expressed a significantly higher level of RFP than the intron-less
construct. Further experiments indicate that the 3'-UTR intron enhances RFP expression by its
intrinsic gene-expression-enhancing activity and by eliminating the inhibitory effect of the premiRNA on the expression of RFP. Based on these findings, we incorporated the intron-embedded
pre-miRNA design into a conditional expression construct that employed the Cre-loxP system.
This construct initially expressed EGFP gene, which was flanked by loxP sites. After exposure to
Cre recombinase, the transgene stopped EGFP expression and began expression of RFP and a
miRNA, which silenced the expression of specific cellular genes.
Conclusion: We have designed and tested a conditional miRNA-expression construct and
showed that this construct expresses both the marker genes strongly and can silence the target
gene efficiently upon Cre-mediated induction of the miRNA expression. This construct can be used
to increase the efficiency of making cell lines or transgenic animals that stably express miRNA
targeting specific genes.

Page 1 of 14
(page number not for citation purposes)

BMC Biotechnology 2008, 8:77

Background
RNAi is a conserved cellular mechanism that can mediate
sequence-specific RNA degradation in eukaryotes [1] and
has recently been harnessed for reverse genetics in mammalian cells and transgenic animals [2-5]. Many shRNA
and miRNA transgene constructs have been designed and
successfully used. The earliest type was composed of a Pol
III promoter and a DNA sequence encoding a shRNA [610]. This type of constructs was constitutively active and
was relatively inefficient in targeting the endogenous
genes when pronuclear injection method was used to
insert the transgene into the genome [7,11]. To overcome
this limitation, several groups transfected cultured mouse
embryonic stem cells, screened for clones where the transgene was active and then used those clones to produce
transgenic mice [7,8,10]. Other groups used lentivirus to
insert transgenes [12-14] or Pol II-promoter-based
miRNA expression constructs, which drive the synthesis of
a miRNA [15,16]. These approaches have achieved silencing of endogenous genes and specific loss-of-function
phenotypes in transgenic mice.
To further improve the in vivo reverse genetics approach
using RNAi, we need to overcome several shortcomings of
the currently used transgene constructs. First, extremely
high levels of shRNA expression should be avoided
because such high levels of shRNA can induce non-specific toxicity [17]. The commonly used Pol III promoter
U6 is a very strong and constitutively active promoter [18]
that can drive shRNA expression to a very high level,
which may lead to non-specific suppression of the endogenous miRNA expression [19,20]. By comparison, pol II
promoters drive miRNA expression at lower levels and
may be advantageous [4,21].
Second, although the constitutively active constructs work
in cells and transgenic mice, a conditional silencing is
more desirable. For example, if a target gene is essential,
use of constitutively active constructs often yields no useful transgenic founders. This is because once injected into
the embryo, the transgene immediately expresses the
shRNA or miRNA, resulting in the silencing of the target
gene and the death of the embryo. This problem can be
avoided by using conditional constructs, which will not
express the shRNA or miRNA when first injected, thus
allowing the transgenic founders to be generated. Additionally, there is a need in biomedical research to understand hypomorphic phenotypes of a gene in a specific
type of cells or at a specific time. A conditional construct
will afford investigators this capability.
Third, coexpression of a reporter gene and a miRNA by
one promoter can facilitate identification of miRNA
expression in cells and in transgenic animals. One strategy
for coexpression is to use a miRNA cassette inserted into
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the 3'UTR of a reporter gene, which has been explored by
previous studies [22,23]. A shortcoming in this design is
that the processing of primary miRNA (pri-miRNA) by
Drosha will cause the mRNA to lose their 3' polyadenylation, which destabilizes the mRNA and reduces levels of
the reporter gene expression. One solution to this problem is to embed the pre-miRNA in an intron as an intronic
miRNA, which is common in many genomes [24]. Lin
and colleagues [25] applied this strategy using an artificial
in-frame intron placed within the open reading frame
(ORF) of a reporter gene. This strategy is ingenious but relatively difficult to apply widely because one has to find
sequences required for splicing (AG/GC with exon-splicing enhancers (ESEs) in its proximity) within the ORF,
and this sequence requirement cannot always be met in
an ORF.
In this report, we designed a new Pol II-based construct
that overcomes these shortcomings. This construct uses a
Pol II promoter to drive expression of the EGFP gene that
is flanked by loxP sites. This feature will allow convenient
screening for cells or transgenic mice where the transgene
is active. Downstream to the EGFP gene is the gene encoding red fluorescent protein (RFP). In the 3' UTR of the RFP
gene, we inserted an artificial intron containing a DNA
sequence encoding a pre-miRNA. We show that this construct expresses EGFP under basal conditions. When
induced by Cre recombinase, it drives expression of RFP
and the miRNA that silences its target gene. We conclude
that this construct may be used as a backbone for conditional gene silencing in transgenic mice.

Results
Finding efficient shRNAs against E1k and E2k subunits of
KGDHC
We selected the E1k and E2k subunits of α-ketoglutarate
dehydrogenase complex (KGDHC) as the targets for testing our miRNA-expressing constructs. KGDHC is a key
enzyme in mitochondrial tricarboxylic acid (TCA) cycle
and is essential for mitochondrial energy metabolism [2629]. Dysfunction of KGDHC has been observed in the
brains of Alzheimer's disease and could cause metabolic
deficiency that is associated with the disease [30-35]. To
build a miRNA expression construct that targets the E1k or
the E2k subunit, our first step was to find shRNAs that can
efficiently silence these two genes. We designed and constructed eight shRNAs targeting each of these two subunits. We used U6 promoter to drive the expression of these
shRNAs (Figure 1A) and tested these constructs by transfecting them into mouse NF-1 cells. Forty eight hours after
the transfection, we determined the mRNA levels of these
two subunits using Northern blot. We used a serial dilution of RNA extracted from the cells transfected with a
construct expressing scrambled shRNA as a standard (Figure 1B, C, shR-Scr lanes 1–5). This scrambled shRNA did
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Figurefor
Screen
1 shRNAs that silence E1k and E2k expression
Screen for shRNAs that silence E1k and E2k expression. Eight shRNAs for each subunit were designed and constructed
as described in Methods. (A) The structure of the shRNA-expressing constructs and an example for the shRNAs. (B) A Northern blot detecting silencing of the E1k subunit. Total RNA samples were prepared from cells 48 hours after transfection with
the vectors shown in (A). Northern blot was carried out as described in Methods. The left five lanes are a dilution series of
total RNA extracted from mouse NF1 cells transfected with a construct that expresses a scrambled shRNA (shR-Scr). The
numbers at the bottom indicate the relative amount that was loaded in each lane. One hundred equals to 6 μg total RNA. In
the right eight lanes, 6 μg total RNA extracted from cells transfected with each of the eight shRNAs against the E1k subunit
were loaded. The probe detects the endogenous E1k mRNA. The numbers at the bottom indicate the relative density of the
E1k band. (C) A Northern blot detecting silencing of the E2k subunit was done in the same way as in (B). The loading arrangement is the same as in (B) except that one hundred in the standard equals to 20 μg of total RNA. Twenty μg also is the amount
of total RNA loaded in each sample lane.

not show any silencing activity towards these two genes
(data not shown). By comparing to the standard, we
found many excellent shRNAs that silenced the expression
of E1k and E2k by more than 80% (Figure 1B, C).

Placing miRNA in an intron does not affect the miRNA
expression and target silencing but increases the reporter
gene expression
We selected one effective hairpin against each of these two
subunits (shR-E1-1, shR-E2-4) and incorporated the stem
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sequences into the pre-miR-30a structure to make miRE1-1 and miR-E2-4, respectively (Figure 2A; also see [36]).
We placed the pre-miR-E1-1 or pre-miR-E2-4 coding
sequence behind a potent Pol II promoter CAG and in the
3'UTR of the RFP gene (Figure 2A). The CAG promoter is
a ubiquitously active and commonly used promoter for
gene expression in cells and in mice [37-40]. To mark the
cells that express the miRNA, the CAG promoter also
expresses RFP (pCAG-RFP-miR, Figure 2A). When transfected into cultured cells, these two constructs expressed
RFP and knocked down their respective mRNAs for E1k
and E2k to a similar degree as their shRNA counterparts
(data not shown).
Many natural miRNAs are in introns of protein-encoding
genes [24]. To determine whether placing a miRNA in an
intron can improve the expression of the miRNA and the
marker gene, we constructed an artificial intron and
placed the pre-miRNA in this intron (pCAG-RFP-miRint,
Figure 2A; also see methods). We placed this intron 10 ntdown stream from the stop codon because introns within
the 50 nt downstream from the stop codon are found in
some eukaryotic mRNAs and do not cause non-sense
mediated decay (NMD) [41]. To test whether this intron
can be successfully spliced, we extracted RNA from the
cells transfected with pCAG-RFP-miRint and carried out
RT-PCR across the splicing junction. We found a single
band with the size of 212 bps that was expected from the
spliced mRNA (Figure 2B). We did not detect any band
with the size of 701 bps that would have been derived
from the unspliced mRNA (Figure 2B). We sequenced the
212-bp PCR product and confirmed that the intron splicing occurred exactly as expected (see legend of Figure 2B).
Thus, the artificial intron functions as designed. To compare pCAG-RFP-miRint with pCAG-RFP-miR, we transfected both constructs into the NF1 cells and determined
their knockdown of target genes. By Northern blots, we
detected no difference between these two constructs in
their degree of knockdown of E1k and E2k mRNAs (Figure
2C), suggesting that intron placement of pre-miRNA
encoding sequence does not increase the miRNA production. To confirm this, the pre-miR-E2-4 and miR-E2-4 levels were measured and the levels did not differ between
the pCAG-RFP-miR and pCAG-RFP-miRint (Figure 2D).
These results suggest that placing a pre-miRNA in an
intron does not increase the miRNA expression.
In order to determine whether the intron influences the
expression of RFP, we compared the RFP expression after
transfecting these constructs into the NF1 cells. The results
revealed two roles of the intron. First, the intron enhanced
the expression of RFP by more than twofold (compare
panels g with h in Figure 3A, and bars g with h in Figure
3B, p < 0.01) despite an existing intron in the 5'UTR of the
RFP gene in this construct. Second, a pre-miRNA in the 3'
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UTR of the RFP gene inhibited the RFP expression by 50%
or more (compare panels a, c and e with panel g in Figure
3A, and bars with the same letters in Figure 3B, all p <
0.05). Placing the pre-miRNA in an intron, however, eliminated this inhibitory effect of the pre-miRNA (compare
panels b, d and f with a, c and e, respectively in Figure 3A,
and bars with the same letters in Figure 3B, all p < 0.01).
In order to establish whether the enhancing effect of the
intron on RFP expression is a result of elevated mRNA levels, we examined RFP mRNA using Northern blot. Addition of intron increased mRNA levels by ~10% (compare
lane 3 with lane 2 in Figure 3C). On the other hand, placing the pre-miRNA in the 3'-UTR of the RFP gene reduced
the RFP mRNA by ~10–20% (compare lanes 1, 5 and 7
with lane 2 in Figure 3C) and resulted in a lower band
(~1.5 kb, lanes 1, 5 and 7 in Figure 3C) that was consistent
in size with the band expected from Drosha cropping. By
placing the pre-miRNA in the intron, the decrease of
mRNA levels caused by the presence of pre-miRNA in the
3'-UTR was largely prevented, and there was no lower
band (lanes 4, 6 and 8 in Figure 3C). Overall, the changes
in the mRNA levels caused by the addition of the intron
did not fully account for the changes in RFP expression,
suggesting that other post-transcriptional mechanisms
also contribute to the increased levels of RFP expression.
To further determine the effect of primary miRNA (primiRNA) processing on the expression of miRNA, we
silenced the expression of Drosha by transfecting the cells
with a construct that expresses Drosha shRNA (U6-shRDrosha) [16]. Silencing Drosha led to the recovery of RFP
expression in constructs with the pre-miRNA placed
directly in their 3'-UTR (see pCAG-RFP in Figure 4, p <
0.05 for both miR-E1-1 and miR-E-2-4) but lowered the
RFP expression somewhat in constructs with the premiRNA embedded in an intron, although this did not
reach statistical significance (see pCAG-RFPint in Figure
4). These results indicate that Drosha processing causes
inhibition of RFP expression and placing the pre-miRNA
in the intron makes the RFP expression independent from
Drosha processing.
An inducible construct with fluorescent indicators for
expression of miRNA
Having determined that intron-embedded pre-miRNA
construct is superior, we incorporated this design in a conditional expression construct based on the Cre-loxP system (Figure 5A). The construct structure is based on the Z/
AP construct that has been previously used in transgenic
mice to express protein-encoding genes [42]. In the Z/AP
construct, we replaced the reporter genes LacZ and human
placental alkaline phosphatase gene, with EGFP and RFP,
respectively. The resulting construct initially expresses
EGFP gene, which is flanked by loxP sites. After induction
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Figure 2 (see legend on next page)
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Design
Figure and
2 (see
testprevious
of Pol II-driven
page) miRNA-expression constructs
Design and test of Pol II-driven miRNA-expression constructs. (A) A schematic illustration of the construct design.
From top to bottom: an example of miRNA against the E1k subunit (the bold, underlined sequence complements the E1k
mRNA); construct pCAG-RFP-miR that constitutively expresses RFP and a miRNA, which is placed in the 3'-UTR of the RFP
gene; construct pCAG-RFP-miRint that constitutively expresses RFP and a miRNA that is placed in an intron located in the 3'UTR of the RFP gene; and structure of the artificial intron (SS = splicing site, BrP = branch point with the sequence TCCTGACCATTCAT, PPT = poly pyrimidine track with the sequence CCTCTTTCTTTTTCCT, and ESE = exon splicing enhancer
with the sequence TTGTGGAAGAAAT). (B) Detection of intron-splicing in RNA extracted from NF1 cells that were transfected with pCAG-RFP-miR-E1-1int. The RT-PCR product was resolved on a 2% agarose gel (lane 1). MW (molecular weight)
lane shows the 100 bp DNA ladder (New England Biolab). The PCR product was sequenced and the spliced exon junction
sequence was ...TAATTAATTAACAG/GCTTGT..., which matched exactly as predicted from the correctly spliced junction.
(C) Northern blots detecting E1k and E2k mRNAs. The RNA was extracted from cells 48 hours after transfection with the
constructs pCAG-RFP-miR or pCAG-RFP-miRint. Ethidium bromide staining is shown as loading controls. (D) Northern blots
detecting the pre-miR-E2-4 and miR-E2-4. The constructs pCAG-RFP-miR and pCAG-RFP-miRint were used in the transfection. The mark on the right side of the pre-miR-E2-4 gel indicates the position of a 60 nt single stranded DNA. The mark on
the right side of the miR-E2-4 gel indicates the position of a 22 nt single stranded DNA.

with Cre, the EGFP gene is excised, and its expression
ceases, leaving the CAG promoter to express RFP and the
miRNA (Figure 5A). The EGFP fluorescence allows convenient monitoring of transgene expression in transfected
cells or in vivo and can facilitate the subsequent analysis.
We tested this construct by transfecting it with or without
a Cre-expressing plasmid. Without Cre, only EGFP was
expressed; with Cre, EGFP expression diminished but RFP
expression appeared (Figure 5B). To further test whether
the miRNA expression was regulated according to our
design, we determined the target knockdown. We detected
no knockdown of the mRNA targets without Cre (Figure
5C) and significant knockdown with Cre (Figure 5D).
Thus, this construct worked as designed.
Finally, to determine whether this construct can knock
down the target protein levels, we measured KGDHC
activity in cells transfected with pCAG-RFP-miRNAint
(Figure 5A). We observed a robust knockdown of the
KGDHC activity by targeting either the E1k or the E2k
subunit (both p < 0.01) (Figure 5E).

Discussion
We have designed a conditional expression construct for
miRNA expression, pCAG-EGFP/RFP-miRNAint (Figure
5A). This construct initially expresses EGFP. When
exposed to Cre recombinase, the loxP-flanked EGFP gene
is excised, allowing the CAG promoter to drive the expression of the miRNA and the marker RFP. This construct will
be useful for generating conditional silencing in transgenic mice and will have several advantages compared
with the currently available transgenic silencing constructs. For example, the constitutive Pol III or Pol II promoter-based constructs are inefficient in generating
transgenic animals with high levels of knockdown [7,11].
Although, by screening for transfected ES cells with high
levels of knockdown or using lentiviral delivery, trans-

genic mice with hypomorphic gene functions have been
generated [10,12,13], these technologies are more complex and more costly than pronuclear injection. Furthermore, it will be difficult to obtain transgenic lines with a
high degree of gene silencing if one targets an essential
gene, because founders with high levels of shRNA or
miRNA expression cannot survive. While this problem
might be partially circumvented by expressing miRNA
using a tissue-specific promoter [15], the conditional
approach that we have designed here will be more versatile and a superior solution to this problem. By crossing
with different Cre-expression lines, one can induce specific gene silencing in many different tissues from a single
line of mice made with this conditional construct. Transgenic silencing mice can be made with conditional constructs using pronuclear injection method [2,43,44] or
using more complex methods such as ES cell screening or
lentiviral delivery. In addition, compared with the inducible transgenic RNAi constructs that have been reported in
the literature, our conditional construct has the following
advantages: It expresses EGFP before induction of the
miRNA, thus affording a convenient screen for transgenic
lines with desirable expression pattern. When crossed
with a Cre driver transgenic line, the coexpression of RFP
and miRNA will provide a convenient and precise indication as to in which cell type gene silencing is occurring.
While developing this construct, we compared the effects
of placing the pre-miRNA in an intron with the effects of
placing the pre-miRNA directly in the 3' UTR of the RFP
gene. Our results indicate that placing the pre-miRNA in
an intron does not increase the miRNA expression (Figure
2) but enhances the marker protein RFP expression (Figure 3). This conclusion agrees with a previous report,
where a pre-miRNA was placed in a 5' intron in the EGFP
gene [45]. Our analysis, however, further revealed that the
intron enhances the RFP gene expression by two effects.
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Figureof3 pre-miRNA and intron on RFP expression
Effects
Effects of pre-miRNA and intron on RFP expression. (A) Representative photographs of cells that were transfected
with various RFP-expressing constructs 48 hours before photographing. a, c and e were transfected with pCAG-RFP-miR constructs. b, d, f were transfected with pCAG-RFP-miRint constructs. g was transfected with pCAG-RFP, which does not contain
a pre-miRNA. h was transfected with pCAG-RFPint, which has an intron but no pre-miRNA. (B) Quantification of RFP levels
from the experiment represented in (A). (C) Northern blot detecting RFP mRNA synthesized by various pCAG-RFP constructs. The table on the top shows whether the construct contains miRNA or/and intron. The numbers in the bottom indicate the relative levels of mRNA (the thick band) that are normalized to lane 2, which is set at 10. Six μg of total RNA was
loaded for each lane.
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Figureof4 Drosha on RFP expression
Effects
Effects of Drosha on RFP expression. Cells transfected with U6-shR-Drosha were cultured for 24 hours and then transfected with various pCAG-RFP constructs. After another 24 hours, RFP fluorescence was observed (A) and quantified (B).
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Figure 5 (see legend on next page)
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Figure
Design and
5 (see
testprevious
of a Cre-inducible
page)
miRNA-expression construct with fluorescent markers
Design and test of a Cre-inducible miRNA-expression construct with fluorescent markers. (A) The basic construct of pCAG-EGFP/RFP-miRNAint is composed of the CAG promoter, a loxP site, the EGFP gene with 3 consecutive SV40
poly A signals (to ensure the cessation of the Pol II synthesis), a second loxP site, the RFP gene, a 3' UTR carrying the premiRNA hairpin, and a poly A signal. Cre mediates the excision of EGFP and the 3 poly A signals, allowing the CAG promoter
to synthesize RFP and miRNA. (B) Top: after transient transfection with pCAG-EGFP/RFP-miRNAint and without Cre, EGFP
was expressed and RFP was not. Bottom: cotransfection with Cre diminished EGFP expression and induced the RFP expression. (C) Northern blot of RNA extracted from cells transfected with pCAG-EGFP/RFP-miRNAint carrying miRNA against E1k
or E2k but without Cre (lane 1). Lanes 2–6 are standard dilution of the RNA extracted from cells transfected with the scrambled miRNA construct. The relative RNA loadings are indicated at the bottom. One hundred represents 6 μg RNA for E1k
blot (top) and 20 μg RNA for E2k blot (bottom). β-actin was detected as a loading control. (D) Northern blot of RNA
extracted from cells cotransfected with pCAG-EGFP/RFP-miRNAint carrying miRNA against E1k or E2k and CMV-Cre (lane
7). Lane 1 is RNA from cells transfected with constitutively expressing pCAG-RFP-miRNAint constructs, which serve as positive knockdown control. Lanes 2–6 are standard dilution of the RNA extracted from cells transfected with the scrambled
miRNA construct. The relative RNA loadings are indicated at the bottom. One hundred represent 6 μg RNA for E1k blot
(top) and 20 μg RNA for E2k blot (bottom). β-actin was detected as a loading control. (E) Confirmation of protein knockdown
by measurement of KGDHC activity. Three days after transfection of constructs CAG-RFP-miR-E1-1int, -miR-E2-4int or -miRScrint, NF-1 cells were lysed and assayed for KGDHC activity as described in Methods.

First, intron can directly enhance the protein gene expression (compare bar h with bar g in Figure 3). Second, the
pre-miRNA sequence placed in the 3'-UTR exerts an inhibitory effect on the protein gene expression, and this effect
can be removed with the elimination of the pre-miRNA
sequence by the intron splicing (Figure 3). These findings
justify the inclusion of the intron in our conditional
miRNA expression construct.
How the pre-miRNA placed in the 3'-UTR inhibits the RFP
gene expression and why intron placement of the premiRNA eliminates this inhibition remain unknown. One
model, as has been proposed [45], suggests that cropping
of the pre-miRNA from the 3'-UTR by Drosha and DGCR8
complex led to a cleavage in the pri-miRNA, resulting in a
separation between the 5'-Cap and 3'-poly A and the degradation of the residue mRNA, thereby reducing the RFP
expression. By placing the pre-miRNA in an intron, the
cropping of the pre-miRNA might occur in the spliced
intron lariat. Alternatively, the cropping of pre-miRNA
might occur before splicing, but this might not affect splicing [46]. In either case, the integrity of the mRNA will be
protected, thus enhancing the RFP expression.
Changes in the RFP expression are consistent with the
above models. When the pre-miRNA was present in the 3'UTR, the RFP expression was decreased (compare bars a, c
and e with bar g in Figure 3B) and this decrease was prevented by inhibition of Drosha (Figure 4); when the premiRNA was placed in the intron, the RFP expression was
enhanced (compare bars a, c and e with bars b, d, and f,
respectively) and inhibition of Drosha did not affect the
RFP expression (Figure 4). However, at the mRNA level,
the presence of pre-miRNA in the 3'-UTR caused only a
slight decrease (compare lanes 1, 5 and 7 with lane 2 in

Figure 3C); and placing the pre-miRNA in an intron
caused a relatively small increase (compare lanes 1, 5 and
7 with lanes 4, 6 and 8). These changes are not sufficient
to account for the changes in the RFP expression, thus suggesting that protection of mRNA from Drosha/DGCR8
processing is not the only mechanism whereby the intron
placement of the pre-miRNA increases the RFP expression. From our data, it is clear that most of the enhancing
effect of RFP expression is derived from the intrinsic properties of the intron, rather than protecting the mRNA from
Drosha/DGCR8 cropping.
Our data also show that the presence of a miRNA in an
intron does not interfere with intron splicing because the
level of mature mRNA produced from the construct with
intron alone was not higher than those from the constructs with intron containing pre-miRNA (Figure 3C,
compare lane 3 with lanes 4, 6 and 8). Conversely, intron
containing the pre-miRNA does not affect the miRNA
processing because constructs with or without an intron
produced similar levels of miRNA (Figure 2C). Thus,
intron splicing and miRNA processing do not interfere
with each other in a miRNA-containing intron. This conclusion agrees with a previous study [46]. However, our
data also revealed that some pre-miRNA can dampen the
intron-enhanced RFP expression (e.g. compare bar b with
bar h in Figure 3B), possibly by interfering with the translation-enhancing effect of the intron. This observation
indicates that the levels of the reporter gene expression
cannot be used to compare the expression levels of different miRNA because the miRNAs may affect the reporter
gene expression differently. Nevertheless, the reporter
expression levels may be used as an indicator of the same
miRNA expression levels in different cell populations,
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provided that the miRNA processing machinery is not saturated.

restriction enzyme sites PmeI and EcoRI downstream of
the U6 promoter.

Based on our analysis, several improvements in our construct design is worth noting. First, we use a single promoter to drive both the reporter and the miRNA
expression. This is advantageous compared with a commonly used design in Pol III-driven shRNA constructs,
which places a reporter expression cassette on the same
linear sequence with the shRNA expression cassette
[12,13]. Because the synthesis of the reporter and the
shRNA are driven by independent promoters, the reporter
expression does not necessarily represent the shRNA
expression and the degree of silencing. This is especially
worrisome in transgenic animals, where a genomic insertion locus may influence different promoters differently.
Our construct will not have this problem because the
expression of the reporter and the miRNA is driven by a
single promoter. Second, the intron-placement of premiRNA enhances the reporter expression, which improves
from constructs that place the miRNA directly in the 3'
UTR of the reporter [22,23] (Figure 3). Third, our placement of the intron in the 3' UTR makes our construct easily adaptable if one desires to use other reporters. The RFP
in our construct can be easily replaced by any other commonly used reporter. This is advantageous compared with
the construct using an in-frame intron within the open
reading frame [25], where the reporter cannot be easily
replaced.

shRNAs against the E1k and E2k subunits of KGDHC were
designed based on the asymmetry rule [48] as well as
other rules [49]. The shRNA sequences were further
screened by RNAfold analysis http://www.tbi.uni
vie.ac.at/~ivo/RNA/RNAfold.html, which predicts minimum energy for secondary structures and pair probabilities, to exclude sequences with Tm of intrastrand folds
greater than 55°C and by Blast homology searching to
select sequences with minimal similarity with other
mouse genes. The loop sequence (TTCAAGAGA) and the
terminal poly-thymidines (TTTTT) were used for all shRNAs. The sense and antisense strands of shRNAs contain
23 nt. All the sense strands start with a "G" while the antisense strands complement the target mRNA sequences
(Figure 1A). To insert shRNAs into the shRNA expression
vector pEGFP-U6, two strands of synthetic DNA oligonucletides were annealed and cloned into the vector using
the restriction sites PmeI and EcoRI. For each gene target,
a total of eight shRNA plasmids were constructed. All constructs were verified by DNA sequencing. Target sequences
for E1k are: shR-E1-1, GATGAGAAGATCTTGCACATCAA;
shR-E1-2, GCAAGAACTAGCTTTGACGAGAT; shR-E1-3,
GTTTCAACAGATTCGGTGCTATT; shR-E1-4, GCACAACCTAACGTCGACAAACT; shR-E1-5, GATGATGCTCCGGTAACTGTTTC; shR-E1-6, GATCTGGTGTGTTATCGACGA
AA; shR-E1-7, GCAATTAGGACGTTTCAACAGAT; and
shR-E1-8,
GCATCGTATATGAGACCTTCCAT.
Target
sequences for E2k are: shR-E2-1, GTGCAATGCTGACGACTTTCAAT; shR-E2-2, GCAATGCTGACGACTTTCAAT
GA; shR-E2-3, GAGGTTGACATGAGTAACATACA; shRE2-4, GGAAGTGGTGTATAGAGATTATA; shR-E2-5, GATA
TTGAACGGACCATTAATGA; shR-E2-6, GCAGCAGTAGAAGATCCAAGAGT; shR-E2-7, GAGGTTGACATGAGTAACATACA; and shR-E2-8, GCAGATATTGAACGGACCA
TTAA. The scrambled sequence is shR-Scr, GCGATGCTCTAAGGTTCTATCAA.

Conclusion
We have built a conditional miRNA-expression construct
that expresses EGFP initially, and upon induction by Cre
recombinase, expresses RFP and a miRNA, which mediates efficient silencing of the target gene. This construct
can be used to increase the efficiency of making stable cell
lines or transgenic animals that stably express miRNA for
silencing specific genes.

Methods
Plasmid vectors
The pEGFP-U6 short hairpin expression vector (Figure
1A) was constructed by inserting the U6 promoter derived
from BSENU6 [47] into pEGFP-N1 (Clontech) at the
EcoO109I site (all restriction enzymes were obtained
from New England Biolabs unless indicated otherwise).
The U6 promoter fragment was amplified by PCR with
introduction of EcoO109I sites at both ends using a pair
of PCR primers (Forward: 5'-CAAGGCCCTTTGACGTCAATGGGAGTTTGTTTTGG-3'; Reverse: 5'-TTAGGGCCC
GAGCGGATAACAATTTCACACAGGAA-3').
Additionally, the multiple cloning site (MCS) in pEGFP-N1 was
modified by deleting the fragment between Hind III and
Xma I. A shRNA coding sequence was cloned between the

For miRNA expression, vectors based on CAG promoter
were constructed. The lacZ and the human placental alkaline phosphatase (AP) genes in the pZ/AP vector [42] were
replaced with EGFP, synthesized by PCR from pEGFP-N1
(Clontech), and RFP, synthesized by PCR from pDsRed2C1 (Clontech), respectively. One cryptic start codon at the
5'UTR of the original AP gene that was not in frame was
eliminated. These modifications produced a conditional
vector for miRNA expression, pCAG-EGFP/RFP. A synthetic artificial intron (Figure 2A) was designed to contain
typical intron splicing regulatory elements [50-52]. This
intron was placed 10 nt-downstream of the stop codon of
the RFP gene to avoid NMD [41]. A fragment of ~400
bases surrounding the miRNA insertion site was amplified
from the first intron of the vector pUbC-miRNA-EGFP
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[36] with primers 5'-GCAATGACGCGATCGCTAATGCGGGAAAGCTCTTATTCGGGT-3' (forward) and 5'AAGGCATGACGCGTTGTTGCGGCCGCCAGAGGTCCGGCGCCTGT-3' (reverse). The amplified fragment was
digested using AsiSI and MluI and inserted into the artificial intron as stuff DNA, which can carry a miRNA (Figure
2A). This generated construct pCAG-EGFP/RFP-miRNAint
(Figure 5A). By in vitro Cre-mediated excision, EGFP gene
along with its poly A was eliminated to generate pCAGRFP-miRNAint (Figure 5A), which expressed RFP and the
miRNA constitutively.
miRNAs targeting E1k and E2k were derived from the
shRNA sequences and were designed based on the premiR-30a structure (Figure 2A). Each strand of a miRNA
was chemically synthesized. Two strands were annealed
and cloned into the vector pUbC-EGFP as previously
described [36]. The miRNA and its flanking sequences of
about 200 bases at both sides from the vector pUbCmiRNA-EGFP were amplified by PCR and cloned to generate the pCAG-EGFP/RFP-miRNAint or pCAG-RFP-miRNAint vectors as described above.
The intron-less control vector pCAG-RFP-miRNA (Figure
2A) was constructed by amplifying the same miRNA and
its flanking sequences from pUbC-miRNA-EGFP plasmid
with SanDI site at both ends. After digestion with SanDI
(Stratagene), the fragment was inserted directly into the
3'-UTR of the RFP gene at the SanDI site. The vectors U6shR-Drosha and U6-shR-Scr with a shRNA targeting Drosha and a scrambled shRNA, respectively, were described
previously [16].
Cell culture and transfection
Mouse NF-1 cells were maintained in DMEM supplemented with 10% fetal bovine serum (Gibco). Cells were
inoculated the day before transfection, which was performed at ~60% cell confluence using Lipofectamine
2000 (Invitrogen) based on the manufacturer's instructions. For pEGFP-U6-shRNA constructs and the constitutive miRNA expression constructs with CAG promoter, 4
μg DNA was used for each well in a 6-well plate. For the
conditional miRNA constructs under the control of CAG
promoter, 2 μg pCAG-EGFP/RFP-miRNAint and 6 μg
CMV-Cre plasmids were cotransfected. In all experiments
where multiple plasmids were used, the total plasmid
amount was kept constant by supplementing with the
empty vector.
Fluorescence analysis
Cell images with fluorescence were taken using Zeiss Axiovert S100 microscope equipped with Axiocam camera and
appropriate filters and were processed by Openlab software. For fluorescence quantification, total cell lysates
were extracted using 1× reporter lysis buffer (Promega)

http://www.biomedcentral.com/1472-6750/8/77

with sonication and subsequent centrifugation. Protein
concentrations were determined with BCA protein assay
kit (Pierce) according to the manufacturer's instructions.
The fluorescence intensity was determined using Tecan
Safire microplate reader with appropriate excitation and
emission wavelength for EGFP and DsRed2.
Northern blots
Northern blot for mRNA was described previously [53]
and used to determine the target knockdown. Briefly, two
days following transfection, cells were harvested and total
RNA was extracted using STAT-60 total RNA isolation reagent (Tel-Test). All mouse cDNA clones (Clone ID for
E1K: 6417392; clone ID for E2k: 3583936) for probe
preparation were purchased from Open Biosystems. Their
cDNA sequences were verified by DNA sequencing. DIGlabeled probes were synthesized using the PCR DIG probe
synthesis kit (Roche) according to the protocols of the
manufacturer. The probe for RFP mRNA was derived from
pDsRed2-C1 by PCR using primers 5'-GCCTCCTCCGAGAACGTCATCAC-3' (forward) and 5'-TAATACGACTCA
CTATAGGGTGTAGTCCTCGTTGTGGGAGGT-3'
(reverse). The E1k probe was derived from E1k cDNA
using primers 5'-CACAGTCCCTGGTGGAAGCACA-3'
(forward) and 5'-CCATCCGAGGGTCTGTGGTGAAG-3'
(reverse). The E2k probe was derived from E2k cDNA
using primers 5'-GACCAGGTTACCCTGACAACAGGA-3'
(forward) and 5'-GCTGATGGTGAAGGTACCACCATC-3'
(reverse). Dig-labeled RNA size marker was obtained from
Roche. Northern images were visualized with the LAS3000 imaging system and quantified by the Multi-Gauge
software (FujiFilm).

For small RNA detection, RNA samples were prepared
using mirVANA miRNA Isolation Kit (Ambion). Equal
amounts of small RNA (1.5 μg) were resolved by 15% Acrylamide Sequagel (National Diagnostics). The RNA was
transferred to a Nylon membrane (Ambion) with a semidry electroblotter (Owl Scientific). Dig-labeled RNA
probes were synthesized with SP6/T7 Transcription Kit
(Roche). Template DNA was derived from pCAG-RFPmiR-E1-1int and pCAG-RFP-miR-E2-4int by PCR with
primers 5'-GAT CGCTAATGCGGGAAAGCTCTTATTC-3'
(forward) and 5'-TAATACGACTCACTATAG GGAAAAAGAAAGAGGATGAATGGTCAG G-3' (reverse). The probe
was approximately 450 bases long and included the
miRNA and its flanking sequence. Subsequent detection
of the signals was done similar to mRNA Northern blotting with a few modifications. For detection of premiRNA, the probe was hybridized with the membrane at
50°C overnight and then washed twice at 50°C for 15
min. For detection of mature miRNA, the membrane was
hybridized with the probe at 30°C overnight and then
washed twice at 40°C for 15 min.
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RT-PCR to detect the spliced junction
Transfection of pCAG-RFP-miRNAint vector into NF-1
cells was done as described above. Twenty-four hours after
transfection, the RNA was extracted from the cells. The
cDNA was synthesized using the SuperScript III CellsDirect cDNA Synthesis Kit (Invitrogen) according to the
instructions provided by the manufacturer using the following primers: 5'-GCTGGACATCACCTCCCACAACG-3'
(forward) and 5'-ACAGGAGGTGGGGAGCAGGAGA-3'
(reverse). The spliced intron would produce a PCR product of 212 bps while the unspliced intron would produce
a PCR product of 701 bps. Platinum Taq DNA polymerase
(Invitrogen) was used for PCR. The samples were denatured at 94°C for 2 minutes, followed by 35 cycles of (1)
denaturation at 94°C for 30 seconds, (2) annealing at
64°C for 30 seconds and (3) extension at 72°C for 60 seconds. The PCR product was fractionated by electrophoresis on a 2% agarose gel. The amplified fragment was
further purified by PCR purification kit (Qiagen) for
sequencing analysis with the two primers.

XGX and HZ provided the Drosha shRNA plasmid and the
BSENU6 vector. ZX and LQ wrote the manuscript. All
authors have read and approved the final manuscript.

KGDHC activity assay
The activity assay for KGDHC was adapted from Shi et al.
[54]. Three days after transfection with pCAG-RFP-miRE1-1int, pCAG-RFP-miR-E2-4int, or pCAG-RFP-miRScrint, NF-1 cells in 6-well plates were washed twice with
D-PBS buffer (Gibco). Total cell lysates were obtained
after adding 250 μl/well of the lysate buffer followed by
sonication and centrifgation. The lysate buffer contains 50
mM Tris-HCl (pH 8.0), 1 mM Dithiothreitol (DTT), 0.2
mM K2EGTA, 0.4% Triton X-100, and 50 μM leupeptin
(all chemicals were obtained from Sigma unless indicated
otherwise). Forty μl of the supernatant was added to the
160 μl activity assay buffer which consists of 63 mM TrisHCl (pH8.0), 0.63 mM K2EDTA, 1.25 mM MgCl2, 1.25
mM CaCl2, 0.63 mM dithiothreitol (DTT), 0.4 mM thiamine pyrophosphate (TPP), 3.1 mM nicotinamide adenine dinucleotide (NAD), 0.4 mM coenzyme A, 0.13%
Triton X-100, and 0.63 mM 2-ME. After 5 minutes incubation at 30°C, 10 μl of 0.1 M α-ketoglutarate was added to
the reaction. The change of absorbance at A340 nm was
recorded every minute for 18 minutes at 30°C with Tecan
Safire microplate reader and the rates of the change were
determined. The percentages of the rate relative to control
were calculated.

6.

Statistical analysis
Results were presented as mean ± SE. Data were analyzed
by Student's t-test. Differences were considered statistically significant if p < 0.05.
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